Redeye judges that more mature NIPU data, indicating OS and ORR benefits of UV1 addition to double CPI therapy, paves the way for late-stage trials with UV1 in mesothelioma. However, OS data still seem immature, and some question marks remain. We note high discrepancies in PFS readouts from BICR and local investigator assessments, likely requiring phase III data for clarification. Still, OS is the ultimate efficacy endpoint that matters, with PFS merely constituting a proxy for OS in some indications. We increase our estimated LoA for UV1 and valuation.